Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by blogon May 10, 2008 3:17pm
513 Views
Post# 15059385

Analst rating

Analst rating

May 10, 2008 3:24:00 AM

PM Company: ISOTECHNIKA INC Report Headline: 'Lower R&D expense curbs loss in Q1/08; key voclosporin transplant data on the ho' Report Date: May 07, 2008 Current FY EPS Estimate [FY2008]: 0.56 Previous EPS Estimate for Current FY [FY2008]: 0.48 Current Quarter EPS Estimate [Q2]: -0.05 Previous EPS Estimate for Current Quarter [Q2]: N/A Next FY EPS Estimate [FY2009]: -0.19 Previous EPS Estimate for Next FY [FY2009]: -0.29 Current Recommendation: BUY Research Firm: Canaccord Capital Corp Analyst: NEIL MARUOKA ASSOCIATE Industry: HEALTH/DRUGS Estimates reported in CAD

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities